Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Key Laboratory of Otolaryngology Head and Neck Surgery (Capital Medical University), Ministry of Education, Beijing, 100730, China.
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Biomed Pharmacother. 2019 Oct;118:109211. doi: 10.1016/j.biopha.2019.109211. Epub 2019 Aug 9.
The BTF3 is involved in oncogenesis, while the biological roles in HSCC remain unclear. The aim of this study was to explore the impact of BTF3 knockdown on biological phenotypes of human HSCC in vivo and in vitro.
The expression of BTF3 was assessed in HSCC and normal tissues. In vitro experiments were performed to explore impact of BTF3 knockdown on biological phenotypes of human HSCC cell line, including proliferation, cell cycle, and apoptosis. Moreover, nude mice were used to evaluate growth of xenograft tumors. Finally, gene chip was used to explore the potential signaling pathways of BTF3, with confirmation of potential BTF3-related genes.
Our results showed elevated expression of BTF3 was observed in HSCC tumors compared to paired adjacent normal tissues in 68 patients, and positively associated with lymph node metastasis and survival of this HSCC patient cohort. In addition, in vitro experiments showed that BTF3 knockdown significantly impaired regulation of proliferation, cell cycle, and apoptosis, potentially via ATM signaling pathway. Finally, in vivo experiments demonstrated that BTF3 functioned as an oncogene by promoting the development and progression of HSCC tumors, indicating its oncogenic role in HSCC.
This study for the first time demonstrated that expression of BTF3 is upregulated in HSCC tumors and this upregulation is positively correlated with lymph node metastasis of this malignancy. The oncogenic role of BTF3 is further validated for tumor promotion and progression of HSCC in vivo, indicating that BTF3 is a potential therapeutic target and prognostic biomarker for HSCC.
BTF3 参与肿瘤发生,但其在头颈部鳞状细胞癌(HSCC)中的生物学作用尚不清楚。本研究旨在探讨 BTF3 敲低对体内和体外人 HSCC 生物学表型的影响。
评估 BTF3 在 HSCC 和正常组织中的表达。进行体外实验以探讨 BTF3 敲低对人 HSCC 细胞系生物学表型的影响,包括增殖、细胞周期和凋亡。此外,使用裸鼠评估异种移植肿瘤的生长。最后,使用基因芯片探索 BTF3 的潜在信号通路,并确认潜在的 BTF3 相关基因。
我们的结果显示,在 68 名患者中,与配对的相邻正常组织相比,BTF3 在 HSCC 肿瘤中表达升高,并且与该 HSCC 患者队列的淋巴结转移和生存呈正相关。此外,体外实验表明,BTF3 敲低显著损害了增殖、细胞周期和凋亡的调节,可能通过 ATM 信号通路。最后,体内实验表明,BTF3 通过促进 HSCC 肿瘤的发展和进展发挥致癌基因的作用,表明其在 HSCC 中的致癌作用。
本研究首次证明,BTF3 在 HSCC 肿瘤中的表达上调,并且这种上调与该恶性肿瘤的淋巴结转移呈正相关。BTF3 的致癌作用在体内进一步验证了其对 HSCC 肿瘤促进和进展的作用,表明 BTF3 是 HSCC 的潜在治疗靶点和预后生物标志物。